Cyclopharm (ASX:CYC) Pre-Tax Income : A$-9.01 Mil (TTM As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Cyclopharm's pretax income for the six months ended in Jun. 2024 was A$-7.48 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was A$-9.01 Mil. Cyclopharm's pretax margin was -56.62%.

During the past 13 years, Cyclopharm's highest Pretax Margin was 32.50%. The lowest was -39.82%. And the median was -7.52%.

Cyclopharm Pre-Tax Income Historical Data

The historical data trend for Cyclopharm's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm Pre-Tax Income Chart

Cyclopharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-2.43

-5.84

-4.35

-6.03

-4.19

Cyclopharm Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Pre-Tax Income	Get a 7-Day Free Trial															-2.25	-3.78	-2.66	-1.53	-7.48

Competitive Comparison of Cyclopharm's Pre-Tax Income

For the Medical Distribution subindustry, Cyclopharm's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclopharm's Pre-Tax Income Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cyclopharm's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cyclopharm's Pre-Tax Income falls into.

Cyclopharm Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cyclopharm's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-10.025	+	5.562	+	-0.024	+	0.489	+	-0.192
	=	-4.19

Cyclopharm's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-7.463	+	0	+	-0.023	+	0.112	+	-0.104
	=	-7.48

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-9.01 Mil.

Cyclopharm (ASX:CYC) Pre-Tax Income Explanation

Cyclopharm's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-7.478	/	13.207
	=	-56.62%

During the past 13 years, Cyclopharm's highest Pretax Margin was 32.50%. The lowest was -39.82%. And the median was -7.52%.

Cyclopharm Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Cyclopharm's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cyclopharm Ltd (ASX:CYC) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208

Website

https://cyclopharm.com.au

Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm Headlines

No Headlines